Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Mitra Keluarga Karyasehat Tbk (MIKA.JK)
Jakarta, ID
PT Mitra Keluarga Karyasehat Tbk, operating alongside its various subsidiaries, is primarily engaged in the ownership and management of hospitals across Indonesia. The company provides a comprehensive array of healthcare services, complemented by its pharmacy operations. Its extensive network includes 17 Mitra Keluarga hospitals and 9 Kasih Group hospitals, strategically situated in key Indonesian cities such as Jakarta, Bekasi, Cikarang, Depok, Cibubur, Tangerang, Sukabumi, Karawang, Cirebon, Surabaya, Cibinong, Subang, and Tegal. Established in 1989, the firm maintains its corporate headquarters in Jakarta, Indonesia, and operates as a subsidiary of PT Griyainsani Cakrasadaya.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.21% | -4.21% | -14.15% | -23.21% | -27.78% | -24.48% | -27.20% | -29.46% | -32.59% | -27.78% | -14.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+10.1% Q1'26: +6.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+19.1% Q1'26: +4.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+26.9% Q1'26: +16.8% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+34.2% ★ Q1'26: +32.2% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+27.0% ★ Q1'26: +25.0% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 10 EPS Ana. |
Dec 2027 14 Rev. Ana. 13 EPS Ana. |
Dec 2028 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.14T
est: 2.16T (-0.8%)
|
2.44T
est: 2.47T (-1.4%)
|
2.50T
est: 2.51T (-0.7%)
|
2.71T
est: 2.75T (-1.3%)
|
3.21T
est: 3.16T (+1.4%)
|
3.42T
est: 3.35T (+2.1%)
|
4.35T
est: 4.32T (+0.7%)
|
4.05T
est: 4.15T (-2.4%)
|
4.26T
est: 4.67T (-8.6%)
|
4.87T
est: 4.83T (+0.9%)
|
5.37T
est: 5.37T (-0.1%)
|
5.96T
5.87T – 6.05T
+10.9% YoY
|
6.62T
6.29T – 7.47T
+11.0% YoY
|
7.33T
7.32T – 7.35T
+10.8% YoY
|
| EBITDA |
842.13B
est: 863.78B (-2.5%)
|
1.01T
est: 988.54B (+2.2%)
|
1.00T
est: 1.01T (-0.2%)
|
905.74B
est: 1.10T (-17.7%)
|
1.18T
est: 1.27T (-6.9%)
|
1.36T
est: 1.34T (+1.5%)
|
1.93T
est: 1.73T (+11.3%)
|
1.63T
est: 1.66T (-1.7%)
|
1.56T
est: 1.85T (-16.0%)
|
1.92T
est: 1.92T (+0.1%)
|
2.04T
est: 2.13T (-4.5%)
|
2.37T
2.33T – 2.40T
+10.9% YoY
|
2.63T
2.49T – 2.96T
+11.0% YoY
|
2.91T
2.90T – 2.91T
+10.8% YoY
|
| EBIT |
750.26B
est: 741.33B (+1.2%)
|
908.45B
est: 848.40B (+7.1%)
|
890.37B
est: 863.27B (+3.1%)
|
865.05B
est: 944.47B (-8.4%)
|
1.02T
est: 1.09T (-6.3%)
|
1.18T
est: 1.15T (+2.7%)
|
1.73T
est: 1.49T (+16.6%)
|
1.40T
est: 1.43T (-1.8%)
|
1.28T
est: 1.60T (-20.1%)
|
1.61T
est: 1.66T (-3.1%)
|
1.84T
est: 1.84T (-0.4%)
|
2.05T
2.01T – 2.07T
+10.9% YoY
|
2.27T
2.16T – 2.56T
+11.0% YoY
|
2.52T
2.51T – 2.52T
+10.8% YoY
|
| Net Income |
566.82B
est: 559.47B (+1.3%)
|
695.44B
est: 659.63B (+5.4%)
|
679.81B
est: 660.06B (+3.0%)
|
613.56B
est: 614.60B (-0.2%)
|
730.15B
est: 672.71B (+8.5%)
|
841.67B
est: 783.08B (+7.5%)
|
1.23T
est: 1.12T (+10.1%)
|
1.01T
est: 978.92B (+3.0%)
|
916.13B
est: 1.06T (-13.9%)
|
1.15T
est: 1.19T (-3.3%)
|
1.36T
est: 1.38T (-1.1%)
|
1.50T
1.43T – 1.53T
+8.9% YoY
|
1.70T
1.53T – 1.91T
+13.2% YoY
|
1.93T
1.75T – 2.05T
+13.7% YoY
|
| SGA |
154.71B
est: 169.68B (-8.8%)
|
168.64B
est: 194.19B (-13.2%)
|
183.37B
est: 197.59B (-7.2%)
|
194.90B
est: 216.18B (-9.8%)
|
231.99B
est: 248.63B (-6.7%)
|
238.89B
est: 263.38B (-9.3%)
|
273.64B
est: 339.96B (-19.5%)
|
335.71B
est: 326.28B (+2.9%)
|
394.65B
est: 389.23B (+1.4%)
|
414.72B
est: 402.71B (+3.0%)
|
501.94B
est: 448.17B (+12.0%)
|
497.24B
489.27B – 504.36B
+10.9% YoY
|
552.04B
524.29B – 622.82B
+11.0% YoY
|
611.48B
610.27B – 612.69B
+10.8% YoY
|
| EPS |
39.00
est: 40.23 (-3.1%)
|
48.00
est: 47.43 (+1.2%)
|
47.00
est: 47.46 (-1.0%)
|
42.48
est: 44.19 (-3.9%)
|
51.14
est: 48.37 (+5.7%)
|
59.10
est: 56.31 (+5.0%)
|
86.47
est: 80.25 (+7.7%)
|
71.61
est: 70.39 (+1.7%)
|
65.08
est: 76.01 (-14.4%)
|
82.43
est: 79.99 (+3.0%)
|
98.13
est: 94.34 (+4.0%)
|
105.78
102.67 – 110.08
+12.1% YoY
|
119.62
109.75 – 137.19
+13.1% YoY
|
135.65
125.97 – 147.26
+13.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joyce Vidyayanti Handajani | Corporate Secretary, Legal Officer & Director | — | female |
| Ruddy Lesmana | Head of Internal Audit Unit | — | male |
| Rustiyan Oen | President Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MIKA.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
